0001736699-22-000002.txt : 20221128 0001736699-22-000002.hdr.sgml : 20221128 20221128165022 ACCESSION NUMBER: 0001736699-22-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20221128 DATE AS OF CHANGE: 20221128 EFFECTIVENESS DATE: 20221128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Escient Pharmaceuticals Inc CENTRAL INDEX KEY: 0001736699 IRS NUMBER: 822065265 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-465945 FILM NUMBER: 221426173 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 617-8220 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 D 1 primary_doc.xml X0708 D LIVE 0001736699 Escient Pharmaceuticals Inc 10578 SCIENCE CENTER DRIVE SUITE 250 SAN DIEGO CA CALIFORNIA 92121 (858) 617-8220 DELAWARE MAS Therapeutics, Inc. None Corporation true Joshua Grass 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Executive Officer Director Marcus Boehm 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Executive Officer Kathleen Sereda Glaub 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Jason Hafler 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Peter Hirth 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Kevin Raidy 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director JeenJoo Kang 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Andrew Schwab 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Charles Zuker 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Director Aaron Mishel 10578 Science Center Drive Suite 250 San Diego CA CALIFORNIA 92121 Executive Officer Biotechnology Decline to Disclose 06b false 2022-11-14 false true false 0 120000006 60000006 60000000 The total offering amount is fully committed by investors participating in the initial closing (the "Investors"). The above noted remainder of the offering will be sold to the Investors upon satisfaction or waiver of certain milestone conditions. false 22 0 0 0 false Escient Pharmaceuticals Inc /s/ Joshua Grass Joshua Grass Chief Executive Officer 2022-11-28